These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22843928)

  • 1. Brain metastasis in a patient with a sarcomatoid variant RCC with well-controlled extracerebral metastases by temsirolimus.
    Kikuno N; Kennoki T; Fukuda H; Matsumoto Y; Tsunoyama K; Ban S; Satoh H; Ryoji O
    Anticancer Res; 2012 Aug; 32(8):3443-7. PubMed ID: 22843928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic therapy for sarcomatoid renal cell carcinoma.
    Pagliaro LC; Tannir N; Sircar K; Jonasch E
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):913-20. PubMed ID: 21707288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma.
    Rodríguez Faba O; Breda A; Rosales A; Palou J; Algaba F; Maroto Rey P; Villavicencio H
    Eur Urol; 2010 Aug; 58(2):307-10. PubMed ID: 20347211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].
    Miyake H; Fujisawa M
    Hinyokika Kiyo; 2012 Nov; 58(11):651-4. PubMed ID: 23254795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases.
    Areses MC; Herranz UA; Ferrán BB; Mateos LL; González JG; López RL
    Med Oncol; 2012 Jun; 29(2):795-8. PubMed ID: 21560067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temsirolimus: a safety and efficacy review.
    Bukowski RM
    Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer.
    Schrader AJ; Seseke S; Keil C; Herrmann E; Goebell PJ; Weikert S; Steffens S; Bergmann L; Roigas J; Steiner T
    Eur Urol; 2014 Aug; 66(2):275-81. PubMed ID: 24012472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
    Paule B; Brion N
    Anticancer Res; 2011 Jan; 31(1):331-3. PubMed ID: 21273619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutics for metastatic renal cell carcinoma.
    Hutson TE; Figlin RA
    Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis.
    Pitt M; Crathorne L; Moxham T; Bond M; Hyde C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):41-6. PubMed ID: 21047490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
    Lamm W; Vogl UM; Bojic M; Zielinski C; Klingler C; Kramer G; Schmidinger M
    Acta Oncol; 2012 Jan; 51(1):101-6. PubMed ID: 21736504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
    Paterson C; Jones RJ
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
    Kapoor A; Figlin RA
    Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.